-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：TXT公布第一季度营收为37亿美元（同比增长12%，超出市场预期5.4%），调整后每股收益为1.45美元（同比增长13%，超出预期0.15美元）。航空业务表现突出，营收增长22%至15亿美元，利润增长26%至1.54亿美元，主要得益于喷气式飞机交付量（37架对比31架）和商用涡轮螺旋桨飞机交付量（35架对比30架）的增加。我们认为利润率的提升表明，随着销量恢复正常和运营效率的提高，航空业务的利润率正朝着12%-13%的目标稳步迈进。管理层维持全年航空业务营收增长9%至65亿美元的预期，80亿美元的积压订单为2026年的业绩提供了保障。计划在12-18个月内完成工业部门的拆分，将打造一个纯粹的航空航天和国防业务架构，从而解决投资者长期以来对集团估值折让的反馈。关键催化剂仍然是MV-75从2027年的EMD交付阶段过渡到2028年的LRIP交付阶段，这将推动贝尔公司利润率的提升，因为随着产量在本十年后期达到每年40-60架的交付量。
Related Articles
Research
Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.
$FE
Sectors
Sector Update: Consumer
Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.
$LW
Australia
Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug
The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%
$AZN